Safety considerations in the management of allergic diseases: Focus on antihistamines

K. Yanai, B. Rogala, K. Chugh, E. Paraskakis, A. N. Pampura, R. Boev

Research output: Contribution to journalReview articlepeer-review

46 Citations (Scopus)

Abstract

Objective: To conduct a systematic review of evidence supporting the safety profiles of frequently used oral H1-antihistamines (AHs) for the treatment of patients with histamine-release related allergic diseases, e.g. allergic rhinitis and urticaria, and to compare them to the safety profiles of other medications, mostly topical corticosteroids and leukotriene antagonists (LTRA). Research design and methods: Systematic search of the published literature (PubMed) and of the regulatory authorities databases (EMA and FDA) for oral AHs. Results: Similarly to histamine, antihistamines (AHs) have organ-specific efficacy and adverse effects. The peripheral H1-receptor (PrH1R) stimulation leads to allergic symptoms while the brain H1-receptor (BrH1R) blockade leads to somnolence, fatigue, increased appetite, decreased cognitive functions (impaired memory and learning), seizures, aggressive behaviour, etc. First-generation oral AHs (FGAHs) inhibit the effects of histamine not only peripherally but also in the brain, and additionally have potent antimuscarinic, anti-α-adrenergic and antiserotonin effects leading to symptoms such as visual disturbances (mydriasis, photophobia, and diplopia), dry mouth, tachycardia, constipation, urinary retention, agitation, and confusion. The somnolence caused by FGAHs interferes with the natural circadian sleepwake cycle and therefore FGAHs are not suitable to be used as sleeping pills. Second-generation oral AHs (SGAHs) have proven better safety and tolerability profiles, much lower proportional impairment ratios, with at least similar if not better efficacy, than their predecessors. Only SGAHs, and especially those with a proven long-term (e.g., ≥12 months) clinical safety, should be prescribed for young children. Evidence exist that intranasally applied medications, like intranasal antihistamines, have the potential to reach the brain and cause somnolence. Conclusions: Second-generation oral antihistamines are the preferred first-line treatment option for allergic rhinitis and urticaria. Patients taking SGAHs report relatively little and mild adverse events even after long-term continuous treatments. An antihistamine should ideally possess high selectivity for the H 1-receptor, high PrH1R occupancy and low to no BrH1R occupancy.

Original languageEnglish
Pages (from-to)623-642
Number of pages20
JournalCurrent Medical Research and Opinion
Volume28
Issue number4
DOIs
Publication statusPublished - 2012 Apr

Keywords

  • Antihistamine
  • H1-receptor occupancy peripheral and brain
  • Immunotherapy
  • Intranasal steroid
  • Leukotriene receptor antagonist

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Safety considerations in the management of allergic diseases: Focus on antihistamines'. Together they form a unique fingerprint.

Cite this